NIPT Test in Pregnancy: Which Chromosome Conditions It Screens, What It Misses, and When to Take It

What the test screens for, and what it quietly skips

Every NIPT panel screens for the same three conditions, and these are the ones the test is best at:

Trisomy 21 (Down syndrome). An extra copy of chromosome 21. This is the most common of the three and the condition for which NIPT is most accurate.

Trisomy 18 (Edwards syndrome). An extra copy of chromosome 18. Much rarer than Down syndrome, and babies with it usually die before or shortly after birth.

Trisomy 13 (Patau syndrome). An extra copy of chromosome 13. Also rare, also severe.

The lab figures this out by counting. Your blood should carry a predictable proportion of DNA from each chromosome. If chromosome 21 contributes slightly more than expected, the algorithm flags a higher risk of trisomy 21. It is pattern recognition over millions of fragments, which is why the test needs enough placental DNA to work at all.

Depending on the panel your lab uses, the test may also screen for sex chromosome conditions (Turner syndrome, where one X is missing; Klinefelter syndrome, an extra X in a boy) and sometimes for a handful of microdeletions, small missing pieces of chromosomes, such as 22q11.2 deletion syndrome. These add-on screenings are less accurate than the three main trisomies, and your doctor may or may not order them.

Now the other side of the list, which matters just as much. NIPT does not screen for:

• Single-gene conditions like thalassemia, sickle cell disease, or cystic fibrosis. These need completely different tests. If thalassemia runs in your family, the relevant test is the HPLC-based thalassemia screening test we wrote about recently, not NIPT.
• Structural birth defects like spina bifida (open spine). NIPT reads chromosome counts, not the baby's anatomy. That is what the mid-pregnancy anomaly ultrasound is for.
• Most other chromosome abnormalities. NIPT covers roughly 80 to 90 percent of the chromosome problems an amniocentesis would detect. The remaining fraction, rarer rearrangements and smaller changes, is outside its scope.

A low-risk NIPT result, then, is genuinely reassuring about the three main trisomies. It is not a certificate covering everything.

Who gets the most out of it

The women for whom doctors reach for NIPT first are the ones with a higher starting risk:

• Age 35 or above at delivery (chromosome errors in eggs become more common with age).
• A previous pregnancy affected by a trisomy.
• A family history of chromosome conditions.
• An ultrasound finding that raises a question, such as increased fluid behind the baby's neck.

But here is the shift in the last few years. The American College of Obstetricians and Gynecologists, together with the Society for Maternal-Fetal Medicine, now recommends offering NIPT to all pregnant women, regardless of age or baseline risk. The test is simply more accurate than the older screenings for everyone, and its false-positive rate is far lower, which means fewer women end up needing an invasive procedure after a scare.

So why did your doctor still ask for the NT scan? Because the ultrasound catches things a blood test never will: structural problems, growth issues, the number of babies. NIPT is a chromosome screen. It was never meant to replace the scan.

In practice, across Mumbai's clinics, NIPT has settled into a routine slot around 11 to 13 weeks, right alongside the NT ultrasound appointment. Many gynaecologists now mention it to every patient at the first-trimester visit, not just to older mothers, and couples decide together whether they want it. IVF pregnancies come up often in these conversations too: the test works after IVF, though conception by IVF is one of the factors that can lower the fetal fraction, so the lab likes a slightly later sample in those cases. If your doctor has not brought it up and you are curious, it is a fair question to ask at your next visit. A good doctor will explain what the result would and would not change about your care, and that conversation alone is worth having.

How it compares with the double marker and the older blood tests

If you have already been offered the double marker test, you might wonder whether NIPT replaces it. The short answer: it does a different job, and many doctors want both.

The double marker test belongs to the older generation of screening, the first-trimester combined screen. It pairs an ultrasound measurement, the fluid behind the baby's neck (nuchal translucency, or NT), with two blood markers in the mother: PAPP-A and free beta hCG. A formula combines the mother's age, the NT measurement, and those two hormone levels into a risk figure. It detects roughly 85 to 90 percent of Down syndrome pregnancies, but its false-positive rate sits around 5 percent. One in twenty women gets a "high risk" call that turns out to be nothing, and every one of those women faces the same anxious question: do I now do an amnio?

NIPT changed that arithmetic. Its false-positive rate for Down syndrome is a fraction of one percent, so far fewer women are sent down the invasive-testing path after a false alarm. It also arrives earlier than the second-trimester quad screen, which is drawn at 15 to 20 weeks, when you would rather not be starting the testing conversation.

But the older tests are not obsolete. The double marker's hormone levels also feed into risk assessment for preeclampsia and poor fetal growth, things NIPT never comments on. And only the NT ultrasound shows the baby's anatomy. Think of it this way: the double marker plus NT scan surveys the pregnancy broadly, while NIPT zooms in on chromosomes with a sharper lens. Your doctor may order them as a team rather than as rivals. The TORCH panel covers the infection-screening blood work many women are offered in the same trimester, and our post on the beta hCG blood test in pregnancy explains one of the older screening markers in detail.

The 10-week rule: why timing is non-negotiable

NIPT is offered from 10 weeks of pregnancy, and that number is not a suggestion. It is a technical floor.

Early in pregnancy there is simply not enough placental DNA in your blood. The fetal fraction climbs as the placenta grows, and most laboratories need it to be at least 4 percent of the total cell-free DNA before the counting statistics become reliable. Before 10 weeks, a large share of samples fall below that line.

Testing too early is the single most common reason for a "no result" report. It is also the most avoidable. This is why your doctor will check your dating before ordering the test, ideally from an early ultrasound rather than the last period date, which can be off by a week or more. A sample drawn at what turns out to be 9 weeks and 3 days may come back unreportable, while the same blood drawn a week later would have been perfectly fine.

There is no upper limit in the same sense. Once you are past 10 weeks the test stays technically valid through the rest of the pregnancy, but its value shrinks as you approach the point where confirmatory testing and decision-making run out of room. Earlier is better, and 10 to 14 weeks is the sweet spot most clinics aim for.

When the lab says "not enough fetal DNA"

A "no result," "no call," or "insufficient fetal fraction" report lands in roughly 1 to 3 percent of samples. It is alarming to receive, and it is almost never the news it feels like.

The usual reasons, in order of frequency:

The sample was drawn too early. Even with a dating scan, ovulation timing can shift. The fix is a redraw a week or two later, and most second samples report fine.

Higher maternal weight. More of the mother's own cell-free DNA in circulation dilutes the placental share. This does not mean the test "does not work" for heavier women; it means the lab may need a later sample, when the placenta is shedding more DNA.

Twins, or a vanishing twin. Two placentas change the DNA math, and some laboratories handle twins only on validated panels. A very early twin pregnancy that reduced to one can also confuse the picture.

Blood thinners. Low-molecular-weight heparin, used by some women with clotting risks, can suppress the fetal fraction.

Processing or transport issues. Cell-free DNA degrades if a sample sits too long or gets too warm. A well-run collection and a fast trip to the lab matter more here than for most tests.

One honest caveat: a small fraction of repeat no-results turn out to be associated with certain chromosome conditions, including trisomy 18 and triploidy, which themselves lower the fetal fraction. That is why doctors take two consecutive failures seriously and usually move to a detailed ultrasound or discuss diagnostic testing. One failed sample, though, is overwhelmingly a timing or technical story, and the standard next step is simply to redraw.

Reading your report: low risk vs high risk

NIPT reports come in plain language, but the words carry specific weight.

"Low risk" or "screen negative." The lab found no unusual chromosome pattern. For Down syndrome this is very reassuring. It is still not a guarantee: screening tests have false negatives, though for the common trisomies the miss rate is well under 1 percent. And remember the scope list from earlier. Low risk for three trisomies says nothing about thalassemia, spina bifida, or the baby's growth.

"High risk" or "screen positive." The lab found a chromosome pattern suggesting increased risk. This is not a diagnosis. It is a flag that says: look closer.

How seriously should you take a high-risk flag? That depends on which condition and on your own risk profile, and this is where the math gets subtle. A screening test's positive predictive value, the share of positive results that turn out to be truly affected, is highest for the most common condition in the lowest-risk setting. For Down syndrome in an average-risk pregnancy, roughly 8 out of 10 high-risk NIPT results are confirmed on diagnostic testing. For trisomy 13 or 18, which are much rarer, the confirmed share is lower. For the add-on microdeletion screens, it is lower still. Your doctor knows these numbers for the specific panel your lab runs, and this is exactly the conversation to have before any decision.

Thresholds and detection figures vary by laboratory and by test version, so treat any specific percentage in a brochure as approximate. The consistent finding across studies and guidelines is the ranking: NIPT is the most accurate screening test available for the common trisomies, clearly ahead of the older blood screenings, and still a screening test.

One more thing about the report format, because it confuses people. Some laboratories report results as risk figures, like "1 in 12,000," which read like the older screening reports. Others report plain "low risk" or "high risk." A few give a fetal fraction percentage and a quality note. None of these formats is more correct than the others; they are different ways of presenting the same underlying statistics. What matters is the classification and the condition it refers to. If anything on the page puzzles you, call the lab or your doctor rather than decoding it yourself. We would rather answer ten anxious questions than have one patient sit on a misunderstood report for a week.

Questions patients actually ask us at the counter

Is the test safe for my baby? Completely. It is a blood draw from your arm. There is no needle near the uterus and no added risk of miscarriage from the test itself. The small risk people associate with prenatal testing belongs to CVS and amniocentesis, not to NIPT.

How early can I take it? From 10 completed weeks. Earlier than that, the placental DNA share is often too low and the lab may return no result. If your dates are uncertain, get a dating scan first rather than guessing.

Can it tell me my baby's sex? Technically, the test reads the sex chromosomes. In India, however, communicating the sex of the fetus is prohibited under the PCPNDT Act, and laboratories do not disclose it on NIPT reports. Do not order the test expecting that information; you will not receive it, and asking puts the lab in a legal bind.

Is a low-risk result a guarantee of a healthy baby? No test offers that. A low-risk NIPT is strong reassurance about Down, Edwards, and Patau syndromes specifically. It does not rule out other genetic conditions, birth defects, or pregnancy complications. Your anomaly scan and your doctor's regular checks still matter.

My report says "no result." Is something wrong with my baby? Almost certainly not. The most common cause is a sample drawn a touch too early, followed by dilution from higher maternal weight and the occasional transport issue. The usual next step is a redraw in one to two weeks. If the second sample also fails, your doctor will take a closer look with ultrasound and discuss next steps, because persistent low fetal fraction is occasionally linked with certain chromosome conditions. One failure is a logistics story far more often than a medical one.

I already did the double marker test. Do I still need NIPT? They answer different questions. The double marker, together with the NT ultrasound, also flags risks for preeclampsia and growth problems and covers structural assessment that NIPT never touches. NIPT is the sharper chromosome screen. Many doctors order both and read them together. Ask yours what each result would change in your care.

Does it detect thalassemia or sickle cell? No. Those are single-gene disorders and NIPT does not test for them. Carrier screening for thalassemia is a separate blood test, the HPLC-based screening we covered here.

Can I take it if I am carrying twins? Some laboratories validate their NIPT panels for twin pregnancies; others do not. Ask the lab before you book. For three or more babies, NIPT is not considered suitable, and your doctor will plan screening differently.

Does it check for birth defects like spina bifida? No. Spina bifida is a neural tube defect, a structural problem, not a chromosome-count problem. It is picked up by the mid-pregnancy anomaly ultrasound and by AFP-based screening, not by NIPT.

I am 24 with no risk factors. Is this test overkill for me? Not necessarily. The current guidance says the test should be offered to every pregnant woman, not just those over 35. A younger woman's chance of a chromosome condition is lower, but the test is just as accurate for her, and some women want the reassurance while others are comfortable skipping it. It is a personal decision, and a reasonable one either way. What matters is that it is an informed decision, made with your doctor, not a default tick on a form.

If the result comes back high risk

A high-risk result is the moment the test stops being reassuring and starts being useful, which is exactly what it was designed for. What happens next follows a well-worn path.

First, your doctor will refer you for genetic counselling. A counsellor walks through what the specific result means for your specific pregnancy: which condition was flagged, how reliable that particular flag is, and what the options are. Bring your partner if you can. Two sets of ears help when the information gets dense.

Second, confirmatory diagnostic testing. A high-risk NIPT for a trisomy is typically followed by CVS (usually 10 to 13 weeks) or amniocentesis (usually 15 weeks onward). These read the baby's chromosomes directly, which is why they can diagnose rather than estimate. They carry that small procedure-related miscarriage risk, around 0.5 to 1 percent, which your fetal-medicine specialist will discuss openly.

Third, a detailed ultrasound. Even before or alongside diagnostic testing, a careful scan can reveal structural clues that support or question the screening result.

What you should not do is make an irreversible decision on a screening result alone. Every guideline, Indian or international, says the same thing: confirm first. The gap between a high-risk screen and a confirmed diagnosis is uncomfortable, and waiting through it is one of the harder weeks of a pregnancy, but acting on an unconfirmed screen is how healthy pregnancies get ended by mistake. The published false-positive numbers are not abstract; they are other families.

It is also worth saying that some families, on receiving a confirmed diagnosis, choose to prepare rather than to intervene: lining up paediatric cardiology for a baby with Down syndrome, for instance, or simply walking into the delivery room informed. Screening gives you time, and time is useful whatever you decide.

Time is also the reason speed matters here. Confirmatory testing has its own windows: CVS is generally done between 10 and 13 weeks, amniocentesis from about 15 weeks onward. If your NIPT was drawn at 12 weeks and the result comes back high risk at 13, the calendar gets tight for CVS and you may be looking at amniocentesis instead. This is one more argument for taking the test at 10 to 11 weeks rather than drifting into the mid-teens. Nobody wants to compress counselling, a procedure, and a decision into a fortnight, and an early sample is the simplest way to avoid that squeeze. When we hand over a report at the counter, the first thing we check with the patient is the gestational age on it, because everything downstream hangs on that number.

Getting it right

Timing the test

Do: wait until 10 completed weeks, confirmed by a dating scan. The test is at its most reliable from 10 to 14 weeks, when there is enough placental DNA and plenty of room for follow-up if needed.

Don't: rush in at 8 or 9 weeks to "get it over with." Early samples are the top cause of no-result reports, and a redraw costs you the very time you were trying to save.

The paperwork you carry

Do: carry your dating scan and your doctor's prescription to the collection. The lab needs accurate gestational age to interpret the fetal fraction.

Don't: assume the lab can date the pregnancy from the blood sample. It cannot. Wrong dates are a quiet source of wrong conclusions.

Reading the report

Do: read "low risk" as exactly that: low risk for the conditions tested, not a clean chit for the whole pregnancy.

Don't: treat a high-risk result as a diagnosis, or a low-risk result as a reason to skip your anomaly scan. Both mistakes come from expecting the test to be something it is not.

After a high-risk result

Do: ask for a referral to a fetal-medicine specialist or genetic counsellor, and get confirmatory testing before any decision.

Don't: make an irreversible choice on a screening result alone, and don't let anyone rush you past the confirmation step. The waiting is hard; skipping it is worse.

Deciding whether to take it at all

Do: talk it through with your doctor and your partner, including what you would do with each possible result. A test is only useful if its answer would change something for you.

Don't: order it for information it legally cannot give you. In India, foetal sex disclosure is prohibited, full stop.

Booking it in Mumbai

The practical side is the easiest part of this test. No fasting, no special preparation, any time of day. If you are booking from home, our phlebotomists collect across Malad, Kandivali, Borivali, and Goregaon, and the draw itself takes a few minutes: a tourniquet, a quick search for the vein, the familiar sharp scratch, then a cotton ball taped to the crook of your arm. Most women tell us the anticipation was worse than the needle.

Reports take several days to about a week, depending on the lab running the panel, because the sequencing and analysis cannot be rushed. You can check the current price and panel details on the NIPT test page, since pricing varies by panel version and we never quote a number that might be out of date by the time you read this.

NIPT usually arrives as part of a wider first-trimester workup. If your doctor has suggested the broader set of pregnancy blood tests alongside it, the pregnancy antenatal extended panel bundles the common ones, and the pregnancy antenatal infection screening panel covers the infection-screening side. You can browse the full range on our packages page or the complete tests page if you are not sure what to book.

To sum up the essentials: NIPT reads placental DNA in your blood to estimate the risk of three chromosome conditions, it works from 10 weeks, it is a screen rather than a diagnosis, and a high-risk result always deserves confirmation before any decision. Book on 84250 40353. The lab runs 24x7, and if the report raises a question, bring it to your doctor first and to us second. That order matters.

References

• American College of Obstetricians and Gynecologists / Society for Maternal-Fetal Medicine guidance on cfDNA-based NIPT (2020 update recommending screening be offered in all pregnancies), summarized by ASCP
• NHS Inform Scotland: Non-invasive prenatal testing (NIPT)
• University of Arizona Health Sciences: "Noninvasive Prenatal Testing: A New Genetic Screening Tool for Use by Pregnant Women"
• Sanford Health: "Cell-free DNA testing for Down syndrome explained"